Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent oesophageal cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 May 2016
At a glance
- Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary) ; Docetaxel
- Indications Oesophageal cancer
- Focus Adverse reactions
- 22 May 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 01 Dec 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 15 Nov 2011 New trial record